British pharma giant Admits Covishield Can Cause Rare Side Effects

-
AstraZeneca Admits Covishield Can Cause Rare Side Effects Amid Lawsuit

According to a report by The Telegraph (UK), British pharmaceutical company AstraZeneca has acknowledged that its Covid vaccine, Covishield, can lead to rare side effects. Court documents reveal that Covishield, produced by the Serum Institute of India in collaboration with AstraZeneca and Oxford University, may cause a condition resulting in blood clots and low platelet count in rare instances.




AstraZeneca is currently facing a class action lawsuit in the UK, where plaintiffs in 51 cases are seeking damages of up to 100 million pounds over alleged deaths and severe injuries caused by the vaccine. Despite the legal action, the UK government, which has indemnified AstraZeneca from such lawsuits, has yet to intervene in the matter.

The first complainant in the case, Jamie Scott, claims to have suffered a permanent brain injury after receiving the Covishield vaccine in April 2021, leading to blood clot-related complications. AstraZeneca, while contesting the claims, has admitted in court documents that Covishield can, in very rare cases, cause Thrombosis with Thrombocytopenia Syndrome (TTS), characterized by blood clots and low platelet count.

The admission marks a significant reversal from AstraZeneca's previous stance, wherein it denied any causal link between the vaccine and TTS. The company now faces the possibility of compensating victims and their families for vaccine-related injuries.

Despite these developments, AstraZeneca maintains that the vaccine is not defective and its efficacy has not been overstated. However, the company's position contradicts scientific findings linking Covishield to vaccine-induced immune thrombocytopenia and thrombosis (VITT), a subset of TTS.

It's important to note that the information provided here is based on news reports and court documents, and any legal conclusions or implications should be interpreted with caution.







Comments

Post a Comment

Best Blogs

IB Interview Questions: M&A : Level 1 M&A Questions

-
Image
1. Why do companies merge? While are many reasons that companies merge the underlying driver of most M&A deals to expedite growth and/or generate cost savings to create value for the owners of the business. When people say that M&A is an ‘art’ and a ‘science’, what does that mean? The science refers to the mechanical valuation methods (Comps, DCF, etc.), but the art is in making a judgment call on valuation based on the outputs of the various valuation methodologies. 2. Who can pay more when buying a company: a Financial buyer or Strategic buyer? Why? Strategic (i.e. corporate) buyers can typically pay more than Financial (i.e. Private Equity) buyers because strategic buyers typically have overlapping operations that can be removed post-merger to generate cost savings (i.e. Synergies). 3. When are sponsors and corporate buyers on equal footing? When a Financial buyer already owns a competing asset, they can generate synergies (which justifies a higher price) and thus are on mor...
Read more

Getting into Investment Banking: A Comprehensive Guide

-
Image
Introduction Breaking into investment banking (IB) is no small feat, whether you're pre-MBA or post-MBA, from a target or non-target school. While high GPAs and test scores are standard, they are often not enough to stand out. Here’s a strategic approach to help you embark on a successful investment banking career. 1. Network Extensively When your application lands at an investment bank, it’s usually reviewed by a small team of bankers responsible for recruiting from specific schools. Given the competitive nature of this field, networking is crucial. Why Networking Matters: Decision-making bankers are more likely to advocate for you if they know you. Especially vital for non-target school students. Engage with alumni and other connections at your target firms. How to Network: Start reaching out to analysts and associates a few months before core recruiting starts. Look for non-target alumni if you're from a non-target school; they often help each other out. Demonstrate Interest...
Read more